1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Thromboembolism - Pipeline Review, H1 2017

Thromboembolism - Pipeline Review, H1 2017

  • February 2017
  • -
  • Global Markets Direct
  • -
  • 95 pages

Summary

Table of Contents

Search Inside

Thromboembolism - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thromboembolism – Pipeline Review, H1 2017, provides an overview of the Thromboembolism (Cardiovascular) pipeline landscape.

When a blood clot (thrombus) breaks and travels in the blood, this is called a thromboembolism. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the chest wall or leg. Risk factors include hypertension, diabetes mellitus, cigarette smoking, and high cholesterol levels. Treatment includes anticoagulants, thrombolytic therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thromboembolism – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Thromboembolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thromboembolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Thromboembolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 2, 1, 3, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Thromboembolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Thromboembolism (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Thromboembolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Thromboembolism (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Thromboembolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Thromboembolism (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Thromboembolism (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Thromboembolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2016

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • December 2016
  • by Global Markets Direct

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease ...

Acute Lung Injury - Pipeline Review, H2 2016

Acute Lung Injury - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • December 2016
  • by Global Markets Direct

Acute Lung Injury - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Acute Lung Injury – Pipeline Review, H2 2016, provides an overview ...

Sepsis - Pipeline Review, H1 2017

Sepsis - Pipeline Review, H1 2017

  • $ 2000
  • Company report
  • February 2017
  • by Global Markets Direct

Sepsis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sepsis – Pipeline Review, H1 2017, provides an overview of the Sepsis (Infectious ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.